Table 2.

Cox proportional hazards analysis of factors related to recurrence‐free survival in patients with hepatocellular carcinoma who underwent hepatic resection

	Univariable analysis		Multivariable analysis
	Hazard ratio	P	Hazard ratio	P
Age (years)	0·99 (0·97, 1·00)	0·318
Male sex	1·24 (0·85, 1·86)	0·260
HBsAg+	0·83 (0·55, 1·20)	0·340
HCV‐Ab+	1·31 (0·96, 1·78)	0·079
Child–Pugh grade B	1·11 (0·35, 6·74)	0·875
Liver cirrhosis	1·56 (1·10, 2·17)	0·012	1·62 (1·11, 2·34)	0·012
Tumour size	4·08 (1·91, 8·32)	< 0·001	1·48 (0·52, 3·93)	0·447
Macroscopic multiple tumours	2·38 (1·64, 3·37)	< 0·001	1·45 (0·91, 2·23)	0·108
Poor differentiation	1·56 (1·13, 2·13)	0·006	1·04 (0·70, 1·51)	0·838
Microvascular invasion	1·36 (1·00, 1·84)	0·049	1·01 (0·70, 1·47)	0·933
Microscopic intrahepatic metastases	3·88 (2·61, 5·62)	< 0·001	2·95 (1·83, 4·67)	< 0·001
AFP level	170·70 (24·50, 937·00)	< 0·001	27·30 (2·60, 190·00)	0·009
DCP level	6·49 (2·86, 13·00)	< 0·001	2·79 (0·92, 7·55)	0·068
High NLR	1·27 (0·93, 1·75)	0·130
High PLR	1·16 (0·82, 1·62)	0·382
Low LMR	1·80 (1·32, 2·43)	< 0·001	1·47 (1·05, 2·04)	0·022

Values in parentheses are 95 per cent confidence intervals. HBsAg, hepatitis B surface antigen; HCV‐Ab, hepatitis C virus antibody; AFP, α‐fetoprotein; DCP, des‐γ‐carboxyprothrombin; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio; LMR, lymphocyte‐to‐monocyte ratio.